Elanco Animal Health (NYSE:ELAN) updated its FY20 earnings guidance on Wednesday. The company provided EPS guidance of $1.09-1.16 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.11. The company issued revenue guidance of $3.05-3.11 billion, compared to the consensus revenue estimate of $3.08 billion.Elanco Animal Health also updated its FY 2020
Pre-Market guidance to 1.09-1.16 EPS.
ELAN has been the subject of several analyst reports. Morgan Stanley upgraded Elanco Animal Health from an equal rating to an equal weight rating and cut their price target for the company from $34.00 to $32.00 in a report on Thursday, November 7th. Gabelli reiterated a buy rating on shares of Elanco Animal Health in a report on Tuesday, January 14th. UBS Group cut their price target on Elanco Animal Health from $30.00 to $28.00 and set a neutral rating for the company in a report on Wednesday, November 20th. Bank of America upgraded Elanco Animal Health from a neutral rating to a buy rating and set a $34.00 price target for the company in a report on Thursday, December 19th. Finally, Raymond James initiated coverage on Elanco Animal Health in a report on Thursday, January 9th. They issued a market perform rating for the company. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of $33.83.
Shares of ELAN opened at $31.15 on Friday. The stock has a fifty day moving average of $30.54 and a two-hundred day moving average of $28.33. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.67 and a current ratio of 3.12. The company has a market capitalization of $11.28 billion, a PE ratio of 28.52, a price-to-earnings-growth ratio of 2.88 and a beta of 0.73. Elanco Animal Health has a fifty-two week low of $25.25 and a fifty-two week high of $35.46.
About Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.
Featured Article: How is diluted EPS different from basic EPS?
Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.